Cargando…
Should the ApoE genotype be a covariate for clinical trials in Alzheimer disease?
Should the apolipoprotein E (ApoE) genotype be a covariate for clinical trials in Alzheimer disease (AD)? ApoE is a transport protein for lipids, amyloid-beta proteins, and the different phenotypes differentially affect amyloid-beta deposition, neurofibrillary tangle formation, and microglial activa...
Autor principal: | Farlow, Martin R |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2919695/ https://www.ncbi.nlm.nih.gov/pubmed/20537201 http://dx.doi.org/10.1186/alzrt39 |
Ejemplares similares
-
Connections between ApoE, sleep, and Aβ and tau pathologies in Alzheimer’s disease
por: Sadleir, Katherine R., et al.
Publicado: (2023) -
Severe COVID-19 in Alzheimer’s disease: APOE4’s fault again?
por: Xiong, Nian, et al.
Publicado: (2021) -
APOE genotype and Alzheimer’s immunotherapy
por: Pankiewicz, Joanna E., et al.
Publicado: (2017) -
Association of APOE e2 genotype with Alzheimer’s and non-Alzheimer’s neurodegenerative pathologies
por: Goldberg, Terry E., et al.
Publicado: (2020) -
Evidence that an APOE ε4 'double whammy' increases risk for Alzheimer's disease
por: Caesar, Ina, et al.
Publicado: (2012)